Trubion Pharmaceuticals, Inc. (NASDAQ: TRBN) jumped 16.34% to $4.70 in the pre-market session. The 52 week trading range for TRBN is $1.00 - $6.75. So far in 2009, TRBN gained over 218%.

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) moved up 14.29% to $2.40 after Ligand Pharmaceuticals announced new preclinical data on SARM molecule LGD-4033. In the last six months, LGND declined by over 24%. Yesterday, LGND closed at $2.10.

Dyax Corp. (NASDAQ: DYAX) surged 4.25% or $0.15 to $3.80 in the pre-market session. Yesterday, DYAX closed at $3.65. In the last six months, Dyax gained over 60%.

Verigy Ltd. (NASDAQ: VRGY) climbed 11% to $10. Yesterday, VRGY announced that it expects 1Q2010 revenue to be in between $105 to $115 million and loss per share to be in between $0.13 to $0.06. Analysts on an average are expecting VRGY to report loss per share of $0.14 on revenue of $106 million for the first quarter of 2010. VRGY declined by around 6% so far in 2009.

Hibbett Sports, Inc. (NASDAQ: HIBB) increased 5.48% to $20.01 after HIBB raised its earning guidance for the financial year 2010. Yesterday, HIBB closed at $18.97.

Netlist, Inc. (NASDAQ: NLST) moved up 10.93% to $6.29 in the pre-market session. The 52 week trading range for NLST is $0.11 and $6.87. Yesterday, NLST closed at $5.67.

Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech stock have been tendered. Earlier this month, Facet’s [...]

(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation

In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet Biotech common stock for $14.50 per share in cash. The board has determined that the offer [...]

(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer

After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash balance is less than Biogen’s offer price. The deal is valued at [...]

(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech

Yesterday, Biogen Idec (BIIB) reiterated its intention to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, even though Facet turned down the offer saying it was not in the best interests of its shareholders. The offer price represents a 64% premium to Facet’s closing price on September 3, 2009. The deal is [...]

(BIIB) Biogen Maintains Facet Biotech Offer